PMID- 16939544
OWN - NLM
STAT- MEDLINE
DCOM- 20070426
LR  - 20181201
IS  - 1368-5031 (Print)
IS  - 1368-5031 (Linking)
VI  - 60
IP  - 9
DP  - 2006 Sep
TI  - Rosiglitazone is effective and well-tolerated in a range of therapeutic regimens 
      during daily practice in patients with type 2 diabetes.
PG  - 1040-7
AB  - Subjects (N = 22,808) with inadequately controlled type 2 diabetes mellitus 
      (T2DM) were included in a large 6-month observational study in Germany. 
      Rosiglitazone (RSG) was added to existing therapy in line with daily practice, 
      with 19,962 subjects evaluated for efficacy by treatment group: RSG monotherapy 
      (n = 1017), RSG plus metformin (MET) (n = 7160), RSG plus sulphonylurea (n = 
      5033), triple oral therapy (n = 4247), and the remaining subject population (n = 
      2505). Overall, RSG significantly reduced median HbA(1c) and fasting blood 
      glucose by 1.3% and 50 mg/dl over 6 months (p < 0.001 for both). The proportion 
      of subjects achieving glycaemic goals of <or= 6.5% and <or= 7.0% increased from 
      5.7% to 33.8%, and from 13.9% to 55.5%, respectively (p < 0.001 for both). Mean 
      systolic and diastolic blood pressures were reduced in the total subject 
      population by 6 mmHg and 2 mmHg, respectively (p < 0.001 for both). RSG had a 
      neutral or reductive effect on mean weight of most (69%) subjects. Consistent 
      with clinical trial data, RSG mono- or combination therapy improved glycaemic 
      control when used in daily clinical practice and is generally well-tolerated.
FAU - Rosak, C
AU  - Rosak C
AD  - Krankenhaus Sachsenhausen, Department of Diabetology and Metabolic Disorders, 
      Frankfurt, Germany.
FAU - Standl, E
AU  - Standl E
FAU - Reblin, T
AU  - Reblin T
FAU - Stammer, H
AU  - Stammer H
FAU - Seidel, D K
AU  - Seidel DK
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Thiazolidinediones)
RN  - 05V02F2KDG (Rosiglitazone)
SB  - IM
MH  - Blood Glucose/metabolism
MH  - Blood Pressure/drug effects
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy/physiopathology
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage/adverse effects
MH  - Male
MH  - Middle Aged
MH  - Rosiglitazone
MH  - Thiazolidinediones/*administration & dosage/adverse effects
MH  - Weight Loss/drug effects
EDAT- 2006/08/31 09:00
MHDA- 2007/04/27 09:00
CRDT- 2006/08/31 09:00
PHST- 2006/08/31 09:00 [pubmed]
PHST- 2007/04/27 09:00 [medline]
PHST- 2006/08/31 09:00 [entrez]
AID - IJCP1092 [pii]
AID - 10.1111/j.1742-1241.2006.01092.x [doi]
PST - ppublish
SO  - Int J Clin Pract. 2006 Sep;60(9):1040-7. doi: 10.1111/j.1742-1241.2006.01092.x.